Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy

Journal of Medical Virology

Volumn 85, Issue 1, 2013, Pages 55-64

  Kim, Soon Sun ^a   Cho, Sung Won ^a   Kim, Soo Ok ^b   Hong, Sun Pyo ^b   Cheong, Jae Youn ^a  

^a Ajou University School of Medicine   (South Korea)

^b GeneMatrix Inc   (South Korea)

Author keywords

Chronic hepatitis B; Clonal sequencing; HBV DNA; Multidrug resistance; Viral genome

Indexed keywords

ADEFOVIR; ADEFOVIR PLUS LAMIVUDINE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG DOSE SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; GENE REPLICATION; GENE SEQUENCE; HEPATITIS B; HUMAN; HUMAN TISSUE; MALE; MOLECULAR CLONING; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT HEPATITIS B; MUTIDRUG RESISTANT HEPATITIS B; SALVAGE THERAPY; TREATMENT RESPONSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; CLONAL EVOLUTION; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; ORGANOPHOSPHONATES; RNA-DIRECTED DNA POLYMERASE;

HEPATITIS B VIRUS;

EID: 84869223683     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23440     Document Type: Article

References (25)

1. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F. 2010. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139: 1207-1217.
2. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, Trepo C, Zoulim F. 2005. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41: 1391-1398.
3. Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim SO. 2010. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 17: 171-177.
4. EASL. 2009. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 50: 227-242.
5. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. 2010. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 53: 449-454.
6. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Kim HT, Rim KS, Kang MS, Yoo W, Kim SO. 2004. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 40: 837-844.
7. Kim SS, Cheong JY, Lee D, Lee MH, Hong SP, Kim SO, Cho SW. 2012. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. J Med Virol 84: 18-25.
8. Kwon HC, Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. 2009. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 24: 49-54.
9. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133: 1445-1451.
10. Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. 2012. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother 56: 2941-2947.
11. Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, Wang H, Xin S, Zoulim F, Xu D. 2010. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther 15: 1185-1190.
12. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: Update 2009. Hepatology 50: 661-662.
13. Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM. 2009. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 49: 50-59.
14. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60: 247-254.
15. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45: 307-313.
16. Shaw T, Bartholomeusz A, Locarnini S. 2006. HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol 44: 593-606.
17. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. 2006. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol Rev 28: 112-125.
18. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. 2008. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 48: 391-398.
19. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73-80.
20. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F. 2007. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46: 531-538.
21. Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Deny P, Zoulim F. 2009. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 136: 168-176. e162.
22. Warner N, Locarnini S. 2008. The antiviral drug selected hepatitis B virus rtA181T/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48: 88-898.
23. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44: 703-712.
24. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-1608, e1591-e1592.
25. Zoulim F, Locarnini S. 2012. Management of treatment failure in chronic hepatitis B. J Hepatol 56: S112-S122.